Exelixis, Inc. (EXEL)
-NasdaqGS 4.55 0.00(0.00%) May 17, 4:00PM EDT|After Hours
:
4.55 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 4.55 |
|---|
| Open: | 4.57 |
|---|
| Bid: | 4.50 x 5000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 5.79 |
|---|
| Beta: | 2.83 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 4.53 - 4.61 |
|---|
| 52wk Range: | 4.19 - 6.95 |
|---|
| Volume: | 1,370,311 |
|---|
| Avg Vol (3m): | 1,418,530 |
|---|
| Market Cap: | 836.29M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.97 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual MeetingBusiness Wire(Wed, May 15)
- Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Tue, May 14)
- EXELIXIS, INC. FinancialsEDGAR Online Financials(Tue, May 14)
- Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?at Seeking Alpha(Sun, May 12)
- Earnings Volatility Drives These Stocks in a New Directionat Wall St. Cheat Sheet(Sun, May 12)
- Exelixis traders look for more gainsoptionMONSTER(Thu, May 9)
- Exelixis Announces Webcasts of Upcoming Investor Conference PresentationsBusiness Wire(Wed, May 8)
- EXEL Crosses Above Key Moving Average Levelat TheStreet(Wed, May 8)
- 3 Stocks to Get on Your Watchlistat Motley Fool(Wed, May 8)
- Exelixis' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Exelixis Earnings: Here’s Why the Stock is Up Nowat Wall St. Cheat Sheet(Tue, May 7)
- Exelixis, Inc. Earnings Call scheduled for 5:00 pm ET todayCCBN(Tue, May 7)
- Exelixis Announces First Quarter 2013 Financial ResultsBusiness Wire(Tue, May 7)
- Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual MeetingBusiness Wire(Tue, May 7)
- EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 21.66 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.29 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 0.15 |
|---|
Business Summary
Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyros...
View More